223645-67-8

Basic information

• Product Name: k115 free base
• Synonyms: k115 free base;Ripasudil;4-Fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]isoquinoline
• CAS NO: 223645-67-8
• Molecular Formula: C15H18FN3O2S
• Molecular Weight: 323.3857232
• EINECS: -0
• Mol File: 223645-67-8.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 497.2±55.0 °C(Predicted)
• Appearance: /
• Density: 1.293±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.70±0.40(Predicted)
• CAS DataBase Reference: k115 free base(CAS DataBase Reference)
• NIST Chemistry Reference: k115 free base(223645-67-8)
• EPA Substance Registry System: k115 free base(223645-67-8)

Safety Data

• Hazardous Substances Data: 223645-67-8(Hazardous Substances Data)

Usage

Description

K115 free base, also known as Ripasudil, is a close derivative of fasudil and an Rho kinase inhibitor. It was approved in Japan in 2014 for the treatment of glaucoma and ocular hypertension when other therapeutic agents are ineffective or cannot be administered. Ripasudil has also been tested in diabetic retinopathy clinical trials and has shown to promote corneal endothelial cell proliferation, endothelium regeneration, and wound healing.

Uses

Used in Ophthalmology:
K115 free base is used as a therapeutic agent for the treatment of glaucoma and ocular hypertension when other treatments are not effective or cannot be administered. It helps in managing intraocular pressure and improving the patient's condition.
Used in Diabetic Retinopathy Clinical Trials:
K115 free base is used as a potential treatment for diabetic retinopathy, as it has shown to promote corneal endothelial cell proliferation, endothelium regeneration, and wound healing. This application is still under investigation and may offer new treatment options for patients suffering from this condition.

Upstream product

• 223644-02-8 4-fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]isoquinoline hydrochloride 
• 223644-14-2 (S)-4-fluoro-N-[1-(3-hydroxypropylamino)propan-2-yl]isoquinoline-5-sulfonamide 
• 913625-37-3 (S)-6-benzyloxycarbonylamino-4-(tert-butoxycarbonyl)-4-azaheptan-1-ol 
• 1360538-90-4 (S)-6-benzyloxycarbonylamino-4-(tert-butoxycarbonyl)-4-azaheptyl methanesulfonate 
• 949109-35-7 (S)-tert-butyl 3-hydroxypropyl(2-(2-nitrophenylsulfonylamide)propyl)carbamate 
• 949109-36-8 tert-butyl (S)-3-methyl-4-[(2-nitrophenyl)sulfonyl]-1,4-diazepane-1-carboxylate 
• 906820-08-4 4-fluoroisoquinoline-5-sulfonyl chloride hydrochloride 
• 194032-32-1 tert-butyl (S)-3-methyl-1,4-diazepane-1-carboxylate 
• 1360538-86-8 (S)-tert-butyl 4-[(4-fluoroisoquinoline-5-yl)sulfonyl]-3-methyl-1,4-diazepane-1-carboxylate 
• 1360538-87-9 (S)-N-{1-[(3-hydroxypropyl)amino]propan-2-yl}-2-nitrobenzenesulfonamide 
• 1360538-89-1 (S)-2-methyl-1-[(2-nitrophenyl)sulfonyl]-1,4-diazepane 
• 1360538-91-5 (S)-1-benzyl 4-tert-butyl 2-methyl-1,4-diazepane-1,4-dicarboxylate 
• 194032-33-2 4-fluoro-5-isoquinolinesulfonyl chloride 
• 1011466-10-6 (S)-2-amino-N-(tert-butoxycarbonyl)-N-(3-tert-butyldimethylsilanyloxypropyl)propylamine 

Downstream Products

• 223644-02-8 4-fluoro-5-[[(2S)-hexahydro-2-methyl-1H-1,4-diazepin-1-yl]sulfonyl]isoquinoline hydrochloride 

Relevant articles and documents

Preparation method of 1,4-dioazo-cycloheptane derivative

The invention discloses a preparation method of a 1,4-dioazo-cycloheptane derivative. The preparation method comprises the steps of carrying out multiple coupling on a compound of a formula (VI) and a compound of a formula (V) at -5-0 DEG C in aromatic hydrocarbon or a halogenated hydrocarbon solvent in the presence of alkali, after the coupling, removing hydroxyl protection from the compound of the formula (VI) by virtue of TBAF, carrying out self-cyclization by virtue of a Mitsunobu reaction to obtain a compound of a formula (II), and removing amino protection from the compound of the formula (II) by virtue of a hydrochloric acid ethyl acetate solution, so as to obtain the target compound 1,4-dioazo-cycloheptane derivative. The preparation method has the advantages that synthetic steps are few, the reaction condition of each step is mild, and the operation is simple convenient, so that the production cost is lowered; and more importantly, the yield of the 1,4-dioazo-cycloheptane derivative synthesized by the method is high.

NOVEL PRODUCTION METHOD FOR ISOQUINOLINE DERIVATIVES AND SALTS THEREOF

The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (I) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (I) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (III) or a salt thereof with a compound represented by formula (II) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base.

(S)-(-)-1-(4-FLUOROISOQUINOLIN-5-YL)SULFONYL-2-METHYL-1,4-HOMOPIPERAZINE HYDROCHLORIDE DIHYDRATE

(S)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride dihydrate; a process for producing the dihydrate; and a medicinal composition containing the dihydrate. This compound has lower hygroscopicity than anhydrous crystals of (S)-(-)-1-(4-fluoroisoquinolin-5-yl)sulfonyl-2-methyl-1,4-homopiperazine hydrochloride and is superior in chemical stability. It is hence useful as a medicine.